Replies to post #900 on RespireRx Pharmaceuticals Inc (RSPI)

[neuroinv]

On schedule. Nothing bad in re-eval of past primate sample. I could not ask for more at this point. Well, I could, but having the FDA's Robert Temple somersault into Cortex headquarters bearing not only an official lift of the clinical hold but...also offering instant marketing approval for CX717, no PhIII required, just because he feels bad about the negative hit that the unnecessary hold put on Cortex's valuation....that might be asking too much. So I'll settle for the update as received.

NeuroInvestment